CD86 and COVID-19: Balbi et al., reported that serum-derived EVs from COVID-19 ( +) patients express higher surface markers such as CD49e, CD206, CD86, CD133/1, CD69, CD142, and CD20 than healthy controls (COVID-19 (−) patients) [89].